Search
Sumario de resultados
TIpos de contenido
Fecha
-
NewBiotechnology is behind more than 40% of the active ingredients in medications included in...
Over the last 40 years, biotechnology has shaped the landscape of medicine, as evidenced by the fact that 69% of drugs in development are a result of biotechnological advancements.
-
Press releaseBiotechnology is behind more than 40% of the active ingredients in medications included in...
The list, comprised of 268 drugs, is an important tool to support the EU's efforts to ensure the security of the supply chain and prevent shortages of critical medications. Over the last 40 years
-
New#NewAseBioMember | "AseBio is a key reference entity in the Spanish and European biotechno...
Meet BeCytes Biotechnologies, our new member. We talked with Estephan Arredondo Córdova, Technical Director
-
New#NewAllyAseBio | "AseBio represents the meeting place for all the companies in the biotech...
Meet JORI & ARMENGOL, our new ally. We talked to María Sanjuanbenito, ejecutiva de Cuentas.
-
AllyJORI & ARMENGOL CORREDURÍA DE SEGUROS Y REASEGUROS S.L.
JORI is a risk consultancy and insurance brokerage specialized in business insurance, with special expertise in Lifescience. We are partners in the I4CT (Insurance For Clinical Trials) platform
-
EventFood 4 Future
-
EventGerman Biotech Days
-
-
-
-
NewWhy is the establishment of a High Commissioner for Deep Strategic Technologies crucial fo...
In a context where these innovations are advancing rapidly, Spain needs to modernize programs and instruments that enable harnessing our scientific and technological potential, transforming it into
-
-
New"The RNA is being investigated as a promising tool for the treatment of various diseases, ...
We spoke with Ana Isabel Jiménez, General Director of Sylentis, to learn how mRNA technology already provides alternative pathways that allow targeting key proteins involved in the development of
-
NewORYZON awarded with a grant for ORY-4001 from the ALS Association in the U.S.
To explore Oryzon’s clinical candidate ORY-4001 in ALS. The ALS Association to provide 500,000 USD funding.
-
-
-
-
EventBioTrinity
-
NewALLOX, a new Centre for Genomic Regulation spin-off, is launched with the support of Asaby...
The company is developing a proprietary platform technology to design new drugs targeting protein allosteric sites to treat cancer and potentially many other diseases.
-
NewThe biobanks of the Valencian Biobank Network move towards excellence with accreditation a...
All biobanks in the RVB currently have a quality management system certified according to the ISO 9001:2015.
-
NewThe CrisBio technology from Cocoon opens new doors to the production of recombinant protei...
The CrisBio® platform uses a totally different protein expression system, since it uses the pupae of the Trichoplusia NI moth as natural bioreactors for the production of enzymes and recombinant
